New Trial for Patients with Acute Myeloid Leukemia
Dr. Joseph Jurcic, MD, is leading a clinical trial for patients with acute myeloid leukemia, AML, who are in remission but have detectable minimal residual disease, or MRD. The trial will study the safety and tolerability of the drug Actimab-A in the post-remission consolidation setting and include dose finding analyses. It also will study the impact of Actimab-A on MRD as well as progression-free survival rates, as announced recently by Actinium Pharmaceuticals on NASDAQ news. Dr. Jurcic, a member of the Herbert Irving Comprehensive Cancer Center and professor of medicine at Columbia University Irving Medical Center, specializes in the treatment of acute and chronic leukemias. He also directs the Hematologic Malignancies Section at Columbia. For the full article, visit NASDAQ.